These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33119110)

  • 21. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
    Innocenti F; Ou FS; Qu X; Zemla TJ; Niedzwiecki D; Tam R; Mahajan S; Goldberg RM; Bertagnolli MM; Blanke CD; Sanoff H; Atkins J; Polite B; Venook AP; Lenz HJ; Kabbarah O
    J Clin Oncol; 2019 May; 37(14):1217-1227. PubMed ID: 30865548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens.
    Parikh K; Huether R; White K; Hoskinson D; Beaubier N; Dong H; Adjei AA; Mansfield AS
    JAMA Netw Open; 2020 Feb; 3(2):e200202. PubMed ID: 32108894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer.
    Graf RP; Fisher V; Creeden J; Schrock AB; Ross JS; Nimeiri H; Oxnard GR; Klempner SJ
    Cancer Res Commun; 2022 Sep; 2(9):1037-1048. PubMed ID: 36922935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy.
    Ota N; Yoshimoto Y; Darwis NDM; Sato H; Ando K; Oike T; Ohno T
    Jpn J Radiol; 2022 May; 40(5):534-541. PubMed ID: 34860358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
    Friedman CF; Hainsworth JD; Kurzrock R; Spigel DR; Burris HA; Sweeney CJ; Meric-Bernstam F; Wang Y; Levy J; Grindheim J; Shames DS; Schulze K; Patel A; Swanton C
    Cancer Discov; 2022 Mar; 12(3):654-669. PubMed ID: 34876409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.
    McNamara MG; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E
    Cancer Treat Rev; 2020 Sep; 89():102084. PubMed ID: 32738738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Large-Scale Cancer Genomic Analysis Reveals Significant Disparities between Microsatellite Instability and Tumor Mutational Burden.
    Choi J; Park KH; Kim YH; Sa JK; Sung HJ; Chen YW; Chen Z; Li C; Wen W; Zhang Q; Shu XO; Zheng W; Kim JS; Guo X
    Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):712-720. PubMed ID: 38393316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers.
    Mo SF; Cai ZZ; Kuai WH; Li X; Chen YT
    Front Cell Dev Biol; 2023; 11():1209243. PubMed ID: 37305681
    [No Abstract]   [Full Text] [Related]  

  • 30. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
    Zheng M
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer.
    Kim J; Kim B; Kang SY; Heo YJ; Park SH; Kim ST; Kang WK; Lee J; Kim KM
    Front Oncol; 2020; 10():314. PubMed ID: 32232003
    [No Abstract]   [Full Text] [Related]  

  • 33. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
    Klempner SJ; Fabrizio D; Bane S; Reinhart M; Peoples T; Ali SM; Sokol ES; Frampton G; Schrock AB; Anhorn R; Reddy P
    Oncologist; 2020 Jan; 25(1):e147-e159. PubMed ID: 31578273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study.
    Xiao Y; Lu D; Lei M; Xie W; Chen Y; Zheng Y; Wang C; Zhao J; Zhu Z; Zhao X; Huang M; Lin Y; Li Z; Yang L
    Ann Transl Med; 2021 Nov; 9(22):1661. PubMed ID: 34988170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.
    Jung J; Heo YJ; Park S
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37094985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma.
    Song JP; Liu XZ; Chen Q; Liu YF
    World J Clin Cases; 2022 Jan; 10(3):790-801. PubMed ID: 35127895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.
    Fabrizio DA; George TJ; Dunne RF; Frampton G; Sun J; Gowen K; Kennedy M; Greenbowe J; Schrock AB; Hezel AF; Ross JS; Stephens PJ; Ali SM; Miller VA; Fakih M; Klempner SJ
    J Gastrointest Oncol; 2018 Aug; 9(4):610-617. PubMed ID: 30151257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity.
    Karamitopoulou E; Andreou A; Wenning AS; Gloor B; Perren A
    Eur J Cancer; 2022 Jul; 169():64-73. PubMed ID: 35512587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.
    Hillman RT; Lin DI; Lawson B; Gershenson DM
    Gynecol Oncol; 2021 Sep; 162(3):728-734. PubMed ID: 34238613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.